

| | First Event | | | | All (first and subsequent) events | | | | |
|--|---------------------|---------------|------------------------------|----------------|-----------------------------------|------|-----------------------------|-----------------|--|
| | n (KM event rate) | | Cox Hazard ratio [95% CI] | Cox p-value | cumulative events | | LWYY Rate ratio [95% CI] | LWYY p-value | |
| Dapagliflozin (N=8582) | Placebo (N=8578) | Dapagliflozin | | | Placebo | | | | |
| AE-related hospitalization | 2779 (32.2%) | 3036 (34.9%) | 0.89 [0.85-0.94] | <0.0001 | 5539 | 6013 | 0.92 [0.86-0.97] | 0.0050 | |
| Any hospitalization (AE or elective) | 3161 (36.6%) | 3416 (39.4%) | 0.90 [0.86-0.95] | <0.0001 | 6777 | 7290 | 0.93 [0.88-0.98] | 0.0070 | |
| AE-related hospitalization of ≥3 days | 2442 (28.4%) | 2662 (30.8%) | 0.90 [0.85-0.95] | 0.0010 | 4479 | 4910 | 0.91 [0.85-0.97] | 0.0030 | |
| AE-related hospitalization of ≥7 days | 1381 (16.1%) | 1514 (17.5%) | 0.90 [0.84-0.97] | 0.0050 | 2092 | 2262 | 0.92 [0.85-1.00] | 0.055 | |
| Elective Hospitalization | 882 (10.3%) | 921 (10.8%) | 0.95 [0.87-1.04] | 0.27 | 1235 | 1274 | 0.97 [0.87-1.07] | 0.52 | |



